Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 5/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.33 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29748840 | 1.00 | DGAT1 (0.41) | DGAT1NPC1ELANEEGFRIGF1R | |
| SCHEMBL31050029 | 0.85 | DGAT1 (0.40) | DGAT1NPC1EGFRIGF1RSRC | |
| SCHEMBL15155202 | 0.83 | PSMB5 (0.42) | DGAT1NPC1EGFRIGF1RSRC | |
| SCHEMBL30848403 | 0.82 | NPC1 (0.36) | DGAT1NPC1EGFRIGF1RSRC | |
| SCHEMBL30168284 | 0.82 | NPC1 (0.46) | NPC1CNR1CNR2 | |
| SCHEMBL15546774 | 0.81 | POLB (0.39) | DGAT1NPC1EGFRIGF1RSRC | |
| SCHEMBL29514362 | 0.81 | ELANE (0.47) | ELANE | |
| SCHEMBL25001937 | 0.80 | CNR1 (0.45) | NPC1CNR1CNR2 | |
| SCHEMBL30848448 | 0.80 | HTR6 (0.37) | DGAT1NPC1EGFRIGF1RSRC | |
| SCHEMBL26615066 | 0.80 | PSMB5 (0.52) | DGAT1NPC1EGFRIGF1RSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326772-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | KYORIN SEIYAKU KK (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20250326773-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | KYORIN SEIYAKU KK (JP) | 2025-10-23 | — | — | US | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-11414413-B2 | Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-08-16 | — | — | US | disclosed |
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-3492468-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | JAK2, JAK1, JAK3 | DGAT1 3774/4885NPC1 4632/4885ELANE 3804/4885 |
| US-20250326772-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | MRGPRX2, MRGPRX1, MRGPRX4 | DGAT1 933/4885NPC1 54/4885ELANE 934/4885 |
| US-20250326773-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | MRGPRX2, MRGPRX1, MRGPRX4 | DGAT1 933/4885NPC1 54/4885ELANE 934/4885 |
| US-11414413-B2 | Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof | JAK2, JAK1, JAK3 | DGAT1 3774/4885NPC1 4632/4885ELANE 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.